These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 2848896)

  • 1. Blocking of lymphokine activated killer (LAK) cell mediated cytotoxicity by cell-sized beads bearing tumor cell proteins.
    Chong AS; Hersh EM; Grimes WJ
    J Immunol; 1988 Dec; 141(12):4418-24. PubMed ID: 2848896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneity of cell surface structures involved in cytotoxicity mediated by lymphokine activated killer cells.
    Bean P; Agah R; Mazumder A
    J Biol Response Mod; 1990 Feb; 9(1):92-7. PubMed ID: 2181073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics and mechanism of IFN-gamma-induced protection of human tumor cells from lysis by lymphokine-activated killer cells.
    de Fries RU; Golub SH
    J Immunol; 1988 May; 140(10):3686-93. PubMed ID: 3129500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity of lymphokine-activated killer cells induced by IL-2. Separate lymphoid subpopulations lyse tumor, allogeneic blasts, and modified syngeneic blasts.
    LeFor AT; Eisenthal A; Rosenberg SA
    J Immunol; 1988 Jun; 140(11):4062-9. PubMed ID: 3259603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guérin-activated killer cells.
    Brandau S; Suttmann H; Riemensberger J; Seitzer U; Arnold J; Durek C; Jocham D; Flad HD; Böhle A
    Clin Cancer Res; 2000 Sep; 6(9):3729-38. PubMed ID: 10999767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and function of LFA-1 on A-NK and T-LAK cells: role in tumor target killing and migration into tumor tissue.
    Donskov F; Basse PH; Hokland M
    Nat Immun; 1996-1997; 15(2-3):134-46. PubMed ID: 9162263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.
    Rosenstein M; Yron I; Kaufmann Y; Rosenberg SA
    Cancer Res; 1984 May; 44(5):1946-53. PubMed ID: 6608989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Membrane-associated lymphotoxin-expressing lymphokine-activated killer cells up-regulate intercellular adhesion molecule-1 expression on target tumor cells in vitro.
    Kimura K; Abe Y; Horiuchi A; Miyake M; Kimura S
    Cell Immunol; 1995 Aug; 164(1):119-25. PubMed ID: 7634343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
    Kalland T; Belfrage H; Bhiladvala P; Hedlund G
    J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Target cell membrane modification and susceptibility to lymphokine-activated killer cell-mediated lysis. II. Sodium periodate has a differential effect on the lysis of human and murine tumor cells.
    Midis GP; Gupta VK; Fabian DF; Lefor AT
    J Surg Res; 1994 Feb; 56(2):146-54. PubMed ID: 8121171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolation and characterization of cytotoxic granules from human lymphokine (interleukin 2) activated killer cells.
    Lowrey DM; Hameed A; Lichtenheld M; Podack ER
    Cancer Res; 1988 Aug; 48(16):4681-8. PubMed ID: 3260817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance of different tumor cells to lysis by lymphokine activated killer cells can be mediated by distinct mechanisms.
    Bean P; Mazumder A
    Immunobiology; 1992 Jun; 185(1):63-77. PubMed ID: 1398742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human oncogene-transfected tumor cells display differential susceptibility to lysis by lymphokine-activated killer cells (LAK) and natural killer cells.
    Lanza LA; Wilson DJ; Ikejiri B; Roth JA; Grimm EA
    J Immunol; 1986 Oct; 137(8):2716-20. PubMed ID: 3489774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors.
    Rayner AA; Grimm EA; Lotze MT; Wilson DJ; Rosenberg SA
    J Natl Cancer Inst; 1985 Jul; 75(1):67-75. PubMed ID: 2989604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Augmentation by anti-T3 antibody of the lymphokine-activated killer cell-mediated cytotoxicity.
    Ting CC; Hargrove ME; Yun YS
    J Immunol; 1988 Aug; 141(3):741-8. PubMed ID: 3260909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clones derived from human natural killer cells are susceptible to lysis by human interleukin-2-activated killer cells.
    Fujiwara T; Loudon WG; Grimm EA
    Lymphokine Cytokine Res; 1993 Feb; 12(1):45-8. PubMed ID: 8096153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of lymphokine-activated killer- and natural killer-mediated cytotoxicities by neutrophils.
    Shau HY; Golub SH
    J Immunol; 1989 Aug; 143(3):1066-72. PubMed ID: 2787346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation of natural killer cell line NK-92-mediated cytolysis (NK-92-lysis) with the surface markers of major histocompatibility complex class I antigens, adhesion molecules, and Fas of target cells.
    Komatsu F; Kajiwara M
    Oncol Res; 1998; 10(10):483-9. PubMed ID: 10338151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.